Wyeth

Societe Des Produits Nestle S.a.

Solvay Pharmaceuticals, B.v.

Physician's Seal, LLC

Capsugel Belgium Nv

Christopher Richard Diorio

Syed Muzafar Shah

Eric C Ehrnsperger

Daniel Hassan

Fred Hassan

Jonathan Marc Cohen

Kadum A Al Shareffi

Xu Meng

Kadum A Ali

Mahdi Bakir Fawzi

John Lokhnauth

Subodh S Deshmukh

Sripriya Venkata Ramana Rao

Eugene Murphy

Maja Vencl-Joncic

Chang Sup Lee

Mahmoud Mirmehrabi

Wendy Ann Dulin

Kadum A Shareffi

A valerian composition includes valerian and an acidifying agent blended together in a pharmaceutically acceptable hydrogel-forming polymer matrix. An expedited release portion of the dosage form includes 5% to 50% of the valerian and is effective to release the valerian therein within 2 hours from placement in a 0.1 N HCl solution. A sustained release portion of the dosage form includes the remainder of the valerian and is effective to release the valerian therein within 10 hours from placement in a phosphate buffer with a pH of 6.8.

Valerian composition and related methods

Disclosed are various embodiments of lipid multiparticulate compositions comprising at least one active agent, a low flow point excipient, and a high flow point excipient.

Lipid multiparticulate formulations

A valerian composition includes a therapeutically effective pharmaceutical dosage form having a solid core including a polymer in which valerian and a valerian stability improving amount of an acidifying agent are contained. The valerian stability improving amount of acidifying agent being sufficient to impart a pH of 2 to 5 to the polymer.

Controlled-release therapeutic compositions including melatonin combined with sedative and/or analgesic ingredients are described. The compositions have a solid core including melatonin in an acidified polymeric matrix. A sedative ingredient such as GABA receptor agonist may also be in the acidified polymeric matrix. The composition may include an expedited release portion providing a burst release of active ingredients and a sustained release portion providing a sustained release of active ingredients.

Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.

Oral formulations and lipophilic salts of methylnaltrexone

Solid lipid particles comprising a lipid hydrophobic matrix and from about 5 wt. % to about 30 wt. % of curcumin, and methods of making and treatment thereof.

Curcumin solid lipid particles and methods for their preparation and use

The present invention provides an oral pharmaceutical formulation comprising coated spheroids of a kinase inhibitor such as neratinib, which formulation is designed to reduce or eliminate side effects associated with existing oral formulations of kinase inhibitors.

Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea

Oral formulations and lipophilic salts of methylnal trexone

Growing community of inventors

Campbell Hill, NY, United States of America

Christopher Richard Diorio